



Corporate Investor Deck

November 2023



Forward Looking Statements

This presentation contains forward looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, relating to our business and financial outlook, which are based on our current beliefs, assumptions, expectations, estimates, forecasts and projections. In some cases, you can identify forward looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “intends,” “predicts,” “potential,” or “continue” or other comparable terminology. Such forward looking statements include, but are not limited to, statements relating to: expectations regarding future financial performance in the short- and long-term, including, without limitation, revenue (and the source thereof), expenses (including anticipated spend and savings/synergies), adjusted gross margin, adjusted EBITDA loss, free cash flow burn, compound annual growth rate, liquidity runway, and the Company’s ability to generate favorable sales mix of higher gross margin products; expectations regarding investment in inventory and spinal implant sets and regarding product launches and line extensions; availability under the Company’s credit facility; the benefits of initiatives, including investments in a direct sales strategy and in product development and enhancements to existing products; planned discontinuation of products; the Company’s growth and taking of market share; the Company’s ability to lower its manufacturing costs; and the Company’s ability to reduce organization complexity and the benefits thereof. These forward looking statements are not guarantees of our future performance and involve risks, uncertainties, estimates and assumptions that are difficult to predict, including the risks described under the heading “Risk Factors” in our Form 10-K for the fiscal year ended December 31, 2022 and subsequent Form 10-Qs filed with the Securities and Exchange Commission (the “SEC”). Factors that could cause or contribute to such differences may include, but are not limited to: risks related to the integration of the legacy Orthofix and SeaSpine businesses and the ability of the combined company to realize the expected long term financial and other benefits of their merger; surgeons’ and hospitals’ willingness to adopt our newly launched products; the ability of newly launched products to meet the needs of surgeons and patients, including as a result of the lack of clinical validation of products in limited commercial (or “alpha”) launch; continued pricing pressure, whether as a result of consolidation in hospital systems, competitors or others, as well as exclusion from major healthcare systems; the risk of supply shortages and associated disruption to product sales, including as a result of our dependence on a limited number of third-party suppliers for components and raw materials, as a result of the pandemic, or otherwise, and our ability to adequately manage inventory; global economic instability and potential supply chain disruption, including as a result of Russia’s invasion of Ukraine and resulting sanctions; our ability to recruit and retain management and key personnel; our ability to continue to invest in medical education and training, product development, and/or sales and marketing initiatives at levels sufficient to drive future revenue growth; general economic and business conditions in the markets in which we do business, both in the U.S. and abroad; and the other risks and uncertainties more fully described in our periodic filings with the SEC. This list of risks, uncertainties, and other factors is not complete. We discuss some of these matters more fully, as well as certain risk factors that could affect our business, financial condition, results of operations, and prospects, in reports we file from time to time with the SEC, which are available to read at www.sec.gov. Any or all forward looking statements that we make may turn out to be inaccurate (due to inaccurate assumptions that we make or otherwise), and our actual outcomes and results may differ materially from those expressed in these forward looking statements. You should not place undue reliance on any of these forward looking statements. Further, any forward looking statement speaks only as of the date hereof, unless it is specifically otherwise stated to be made as of a different date. We undertake no obligation to update, and expressly disclaim any duty to update, our forward looking statements, whether as a result of circumstances or events that arise after the date hereof, new information, or otherwise.



Extensive Portfolio
Solutions with
Complementary
Technologies



Improved Clinical
Outcomes &
Economic Value



Large Addressable
Markets with High
Growth Opportunities



Expanded Distribution
Channels & Global
Commercial Reach



\$150M Credit Facility
Provides Liquidity to
Fund Growth and Scale



Visionary Leadership
Team with Deep
Sector Experience

Investment Highlights

Building a Leading
Global Spine & Orthopedics
Company

Senior Leadership Team

Experienced leadership with 250+ years in spine/orthopedics



Catherine Burzik
Chair of the Board &
Interim Chief Executive Officer



Suzanne Armstrong
Chief Human Resources Officer



Geoffrey Gillespie
Vice President, Corporate
Controller and Interim Chief
Financial Officer



Roberto Donadello
Senior Vice President
Global Operations



Kim Elting
President
Global Orthopedics



Ehab Esmail
Senior Vice President, Global Quality,
Regulatory & Clinical Affairs



Kevin Kenny
President
Global Spine



Puja Leekha
SVP, Chief Ethics & Compliance
Officer, Interim Chief Legal Officer



Tyler Lipschultz
President
Global Biologics




Beau Standish, PhD, PEng
President
Global Enabling Technologies



Frank Vizesi, PhD
Chief Scientific Officer

Complementary High Growth Portfolio

\$7B of Focused High-Growth Market Segments* | 6.1% CAGR



SmartTRAK® 2022 – 2026 U.S. Estimates
*Focused growth segments include Enabling Technologies, Motion Preservation, Interbody, DBM, LLIF/OLIF, MIS and Long Bone Stimulation
©2023 Orthofix Medical Inc. All rights reserved | 5

Orthopedics

Specialized portfolio of **limb reconstruction and deformity correction** products that address the most challenging orthopedic conditions

Complex Foot & Ankle Reconstruction



TrueLok™

Ring Fixation System



AHN


Ankle Hindfoot Nailing™ System



G-Beam

Fusion Beaming System™

Complex Fracture Management



TrueLok™ EVO

Ring Fixation System



XCaliber™

Hybrid Fixator



Galaxy™

Fixation System

Adult & Pediatric Limb Reconstruction



Fitbone®

Limb-Lengthening System



TL-HEX™


TrueLok Hexapod System



JuniOrtho

Pediatric Plating System™

Digital Healthcare




OrthoNext™

Platform System for Preoperative Planning

Spinal Implants

Comprehensive **best-in-class** spinal implants offering driving **rapid market adoption**

Cervical



M6-C™

Artificial Cervical Disc



NorthStar®

Posterior Cervical Fixation System



Construx™ Mini

PTC Spacer System



Shoreline®

Anterior Cervical Standalone System



WaveForm™ C


3D Interbody



Admiral™

Anterior Cervical Plating System

Thoracolumbar Fixation



Mariner® Deformity

Adult Deformity Posterior Fixation System



Mariner®

Modular Pedicle Screw System



Firebird™ NXG

Spinal Fixation System



Janus™

Fenestrated Screw System

Interbodies



WaveForm™

3D Interbody



Forza™ TI

Ti Spacer System with Nanovate™ Technology



Reef® TO

NanoMetalene® with Reef Topography®



Meridian™

Spacer System



Explorer® TO

Expandable Interbody



ForzaXP™

Expandable Spacer System

Biologics

Full spectrum of biologic solutions

to enhance the fusion process and promote bone repair and growth

Cellular Allograft



Trinity Elite™

Procedural Solutions



OsteoBallast®

**OsteoBallast
MT**

**NorthStar™
Facet Fusion**

Demineralized Bone Fiber



**OsteoStrand®
Plus**



FiberFuse™

Demineralized Bone Putty



**Torrent® & Torrent C
Accell Evo3® & Evo3® c
DynaGraft® II & OrthoBlast® II
Legacy™**

Synthetic



Opus™ BA



Opus™ Mg Set



Mozaik™



OsteoCove™

Graft Delivery



RAPID®



O-Genesis™

Traditional Allograft



Bone Growth Therapies

Safe and effective treatment and non-surgical alternative
to overcome bone healing challenges



#1 Prescribed bone growth stimulator



We are proud to be the first to offer a free recycling program so patients can properly dispose of their devices after use.



PEMF technology approved
Since 1986

1,000,000

Prescribed devices

Bone Healing Therapy



PhysioStim™

Bone Growth Therapy



AccelStim™

Bone Healing Therapy

Spine Fusion Therapy



CervicalStim™

Spinal Fusion Therapy



SpinalStim™

Spinal Fusion Therapy


FLASH™ Navigation with 7D Technology



Enabling Technologies

**Servicing the
full continuum
of surgical care**

Diversified & Complementary Business with Broad Commercial Reach



- Bone Growth Therapies
- Spinal Implants, Biologics, and Enabling Technologies
- Orthopedics

~**83%** U.S. | ~**17%** OUS

Products distributed in **68** countries

Commercial Strategy Framework

Geographic Footprint

Double digit growth in global commercial reach



Focused Distributors

Expanded market penetration with increased dedicated distribution



Diverse Sales Strategy

Cross selling opportunities across direct and distribution-based sales channels



Clinical Relevance

Proven track record of procedural excellence, backed by compelling clinical evidence, spanning multiple markets




Training and Education Programs

Complementary training and education programs to deliver value to surgeons and distributors



Continuum of Care

Comprehensive product portfolio from pre-operative planning through post surgical



Key Growth Drivers



Spinal Fixation

Industry leading product and procedure launches per year & continued penetration into emerging markets



Spinal Implants & Biologics

Continue share taking at >5x market growth, from 50+ product launches since 2018



BGT Fracture

DD growth driven by the recent AccelStim™ launch, future product launches & increasing channel investments



Distributor Partners

Onboard additional transformative & more focused distributor partners



Orthopedics

HSD growth driven by channel expansion and further products launches expanding our leading TrueLok™ and Fitbone™ franchises



Product Utilization

Higher product utilization per procedure from more complete portfolio



Higher Revenue Per Case

Increased participation in higher revenue complex and deformity procedures from recent full commercialization of Mariner® Adult Deformity Platform



Enabling Technologies

Growth from recent full commercial launch of MIS module and higher conversion of revenue earnout arrangements

Orthofix

Q3 2023 Highlights

- (1) Constant Currency is calculated by applying foreign currency rates applicable to the comparable, prior-year period to present the current period net sales at comparable rates. Constant currency can be presented for numerous GAAP measures, but is commonly used by management to analyze net sales excluding the impact of changes in foreign currency rates.
- (2) The reasons for and nature of non-GAAP disclosures by the Company, descriptions of the adjustments used to calculate those non-GAAP financial measures, and reconciliations of those non-GAAP financial measures to the most comparable GAAP financial measure, are provided in the Company's press release issued and Current Report on Form 8-K filed on November 8, 2023.
- (3) See Appendix A for calculation of proforma Adjusted EBITDA and proforma Adjusted Gross Margin for each quarterly period of 2022.
- (4) Pro forma net sales for 2022 include the impact of final Spinal Implant stocking orders to European distributors prior to SeaSpine's exit from that market. Excluding the impact of these transactions, net sales growth was +7.4% on a pro forma constant currency basis for Total Orthofix and +5.8% for Spinal Implants, Biologics, and Enabling Technologies.

\$184M

Q3 2023 Revenue
59.9% Growth YoY at Constant Currency⁽¹⁾
0.3% Proforma Growth YoY at Constant Currency⁽²⁾⁽⁴⁾

\$53.4M

Q3 2023 BGT Revenue
14.7% Growth YoY

\$101M

Q3 2023 Global Spinal Implants, Biologics and Enabling Technologies Revenue
-6.1% Proforma Decline YoY at Constant Currency⁽²⁾⁽⁴⁾

\$29.7M

Q3 2023 Global Orthopedics Revenue
0.7% Growth YoY at Constant Currency ⁽²⁾

\$33.7M

Cash & Cash Equivalents, 9/30/2023
\$70M of outstanding credit facility borrowings

\$13.5M

Adjusted EBITDA
17.1% Proforma Growth YoY⁽²⁾⁽³⁾

71%

Adjusted Gross Margin⁽²⁾

2023

Full Year Guidance



\$739 – 744M Revenue

\$42 – 46M Adjusted EBITDA

Revenue ranges above represent 5.4% to 6.2% proforma growth rates over prior year

Guidance information is as of November 8, 2023, based on guidance provided by Orthofix leadership on that date. Inclusion of this information in this presentation is not a confirmation or an update of, and should not be construed or otherwise assumed to reflect any confirmation or update of, that guidance by Orthofix leadership as of any date other than November 8, 2023.

Merger Highlights



Meaningful Revenue & Cost Synergies

- ✓ Est. Revenue Synergies: >\$25M*
- ✓ Est. Cost Synergies: ~\$50M**
- ✓ Revenue Risk to Manage: ~\$20M***
- ✓ Working Capital & Capex Synergies



Complementary Portfolios

- ✓ #1 Prescribed bone growth stimulator portfolio in the U.S.
- ✓ Broadest advanced DBM portfolio, market leading cellular allograft, and comprehensive line of synthetics
- ✓ Next generation differentiated artificial cervical disc



Broader Commercial Reach

- ✓ Accelerated adoption of differentiated technologies
- ✓ Sustainable growth & value creation
- ✓ Strengthened U.S. and international sales channels
- ✓ Rapid product innovation driving market-share taking

*Revenue synergies of ~\$25M expected by 2025

**Cost synergies of ~\$50M expected by 2025 with incremental opportunity to reduce stock-based compensation expense

***Based on due diligence, including revenue zip code analysis performed by 3rd party



Extensive Portfolio
Solutions with
Complementary
Technologies



Improved Clinical
Outcomes &
Economic Value



Large Addressable
Markets with High
Growth Opportunities



Expanded Distribution
Channels & Global
Commercial Reach



\$150M Credit Facility
Provides Liquidity to
Fund Growth and Scale



Visionary Leadership
Team with Deep
Sector Experience

Investment Highlights

Building a Leading
Global Spine & Orthopedics
Company

**STRONGER
TOGETHER**

THANK YOU

APPENDIX A

Proforma Non-GAAP Financial Measures

Adjusted EBITDA

(\$ in millions)	Q3 22 (Proforma)			NewCo		
	OFIX	SPNE	NewCo	Q3 23	Q3 22	Change
Loss before income taxes	\$ (9.372)	\$ (15.111)	\$ (24.483)	\$ (28.385)	\$ (24.483)	\$ (3.902)
<i>Non-GAAP adjustments</i>						
Interest expense, net	\$ 0.277	\$ 0.149	\$ 0.426	\$ 1.576	\$ 0.426	\$ 1.150
Depreciation and intangible asset amortization expense	7.570	4.341	11.911	13.097	11.911	1.186
Share-based compensation expense	4.728	3.652	8.380	6.274	8.380	(2.106)
Foreign exchange impact and other non-operating expense/(gain)	3.253	0.270	3.523	1.909	3.523	(1.614)
SeaSpine merger-related expenses	2.937	1.412	4.349	5.416	4.349	1.067
Strategic investments	0.455	0.016	0.471	0.913	0.471	0.442
Acquisition-related fair value adjustments	0.419	-	0.419	7.122	0.419	6.703
Loss on investment securities	(0.001)	-	(0.001)	-	(0.001)	0.001
Legal judgments/settlements	0.125	0.544	0.669	3.851	0.669	3.182
Medical device regulation	2.582	-	2.582	1.840	2.582	(0.742)
Business interruption - COVID-19	1.216	-	1.216	-	1.216	(1.216)
Succession and transition charges	0.068	-	0.068	(0.092)	0.068	(0.160)
Spinal set instrument replacement expense	-	1.866	1.866	-	1.866	(1.866)
European sales and marketing organization restructuring	-	0.152	0.152	-	0.152	(0.152)
Total Non-GAAP adjustments	\$ 23.629	\$ 12.402	\$ 36.031	\$ 41.906	\$ 36.031	\$ 5.875
Adjusted EBITDA loss	\$ 14.257	\$ (2.709)	\$ 11.548	\$ 13.521	\$ 11.548	\$ 1.973

On the Company's Q3 2023 earnings call held on November 8, 2023, Orthofix management presented Proforma Adjusted EBITDA and Adjusted Proforma Gross Margin, both of which are non-GAAP financial measures, for the 3rd quarter of 2022. Those proforma non-GAAP financial measures are intended to report the financial impact of the merger with SeaSpine on Adjusted EBITDA and Adjusted Gross Margin as if the merger had occurred on January 1, 2022, in order to assist investors with comparing those proforma results to those same non-GAAP financial measures as reported for the 3rd quarter of 2023.

A reconciliation of proforma Adjusted EBITDA for each quarter of 2022 to the nearest GAAP financial measure for each of SeaSpine and Orthofix is presented on this slide.

For further information on the reasons for and nature of non-GAAP disclosures by Orthofix and descriptions of the adjustments used to calculate non-GAAP financial measures, please see the Company's Current Report on Form 8 K filed on November 8, 2023.

Adjusted Gross Margin

(\$ in millions)	Q3 22 (Proforma)			NewCo		
	OFIX	SPNE	NewCo	Q3 23	Q3 22	Change
Total revenue, net	\$ 113.996	\$ 67.772	\$ 181.768	\$ 184.006	\$ 181.768	\$ 2.239
Gross profit	\$ 83.423	\$ 38.585	\$ 122.008 (1)	\$ 119.763	\$ 122.008	\$ (2.245)
Add back:						
Share-based compensation expense	0.195	0.103	0.299	\$ 0.463	\$ 0.299	\$ 0.164
SeaSpine merger-related costs	-	-	-	2.161	-	2.161
Strategic investments	0.304	-	0.304	0.055	0.304	(0.249)
Acquisition-related fair value adjustments	-	-	-	7.922	-	7.922
Amortization/depreciation of acquired long-lived assets	-	-	-	0.280	-	0.280
Medical device regulation	-	-	-	0.006	-	0.006
Adjusted gross profit	\$ 83.922	\$ 38.688	\$ 122.611	\$ 130.650	\$ 122.611	\$ 8.039
Adjusted gross margin (Adjusted gross profit / Total revenue, net)	73.6%	57.1%	67.5%	71.0%	67.5%	3.5%

(1) SeaSpine gross profit reflects reclassifications of certain expenses to conform to Orthofix presentation.

Historical 2022 Quarterly Proforma Adjusted EBITDA

Proforma Historical Adjusted EBITDA (\$ in millions)	Q1 22			Q2 22			Q3 22			Q4 22			FY 2022		
	OFIX	SPNE	NewCo	OFIX	SPNE	NewCo	OFIX	SPNE	NewCo	OFIX	SPNE	NewCo	OFIX	SPNE	NewCo
Loss before income taxes	\$ (4.389)	\$ (16.832)	\$ (21.221)	\$ 3.042	\$ (15.094)	\$ (12.052)	\$ (9.372)	\$ (15.111)	\$ (24.483)	\$ (6.987)	\$ (20.287)	\$ (27.274)	\$ (17.706)	\$ (67.324)	\$ (85.030)
<i>Non-GAAP adjustments</i>															
Interest expense, net	\$ 0.375	\$ -	\$ 0.375	\$ 0.407	\$ 0.293	\$ 0.700	\$ 0.277	\$ 0.149	\$ 0.426	\$ 0.229	\$ 0.202	\$ 0.431	\$ 1.288	\$ 0.644	\$ 1.932
Depreciation and intangible asset amortization expense	7.516	4.202	11.718	6.512	4.295	10.807	7.570	4.341	11.911	7.421	4.349	11.770	29.019	17.187	46.206
Share-based compensation expense	4.332	2.819	7.151	4.460	3.701	8.161	4.728	3.652	8.380	4.923	3.412	8.335	18.443	13.584	32.027
Foreign exchange impact and other non-operating expense/(gain)	1.242	(0.002)	1.240	2.991	0.266	3.257	3.253	0.270	3.523	(4.195)	(0.147)	(4.342)	3.291	0.387	3.678
SeaSpine merger-related expenses	-	-	-	-	-	-	2.937	1.412	4.349	9.073	2.616	11.689	12.010	4.028	16.038
Strategic investments	0.970	0.372	1.342	1.824	(0.010)	1.814	0.455	0.016	0.471	0.771	(0.016)	0.755	4.020	0.362	4.382
Acquisition-related fair value adjustments	(5.500)	0.125	(5.375)	(10.714)	0.083	(10.631)	0.419	-	0.419	0.200	-	0.200	(15.595)	0.208	(15.387)
Loss on investment securities	0.065	-	0.065	0.123	-	0.123	(0.001)	-	(0.001)	0.001	-	0.001	0.188	-	0.188
Legal judgments/settlements	0.193	-	0.193	0.148	-	0.148	0.125	0.544	0.669	0.337	1.066	1.403	0.803	1.610	2.413
Medical device regulation	1.952	-	1.952	2.246	-	2.246	2.582	-	2.582	3.481	-	3.481	10.261	-	10.261
Business interruption - COVID-19	0.343	-	0.343	0.316	-	0.316	1.216	-	1.216	0.512	-	0.512	2.387	-	2.387
Succession and transition charges	0.010	-	0.010	0.068	-	0.068	0.068	-	0.068	-	-	-	0.146	-	0.146
Spinal set instrument replacement expense	-	1.018	1.018	-	1.665	1.665	-	1.866	1.866	-	2.630	2.630	-	7.179	7.179
European sales and marketing organization restructuring	-	0.279	0.279	-	0.127	0.127	-	0.152	0.152	-	0.426	0.426	-	0.984	0.984
Total Non-GAAP adjustments	\$ 11.498	\$ 8.813	\$ 20.311	\$ 8.381	\$ 10.420	\$ 18.801	\$ 23.629	\$ 12.402	\$ 36.031	\$ 22.753	\$ 14.538	\$ 37.291	\$ 66.261	\$ 46.173	\$ 112.434
Adjusted Proforma EBITDA (proforma for SeaSpine merger)	\$ 7.109	\$ (8.019)	\$ (0.910)	\$ 11.423	\$ (4.674)	\$ 6.749	\$ 14.257	\$ (2.709)	\$ 11.548	\$ 15.766	\$ (5.749)	\$ 10.017	\$ 48.555	\$ (21.151)	\$ 27.404

On the Company's Q3 2023 earnings call held on November 8, 2023, Orthofix management presented Proforma Adjusted EBITDA and Adjusted Proforma Gross Margin, both of which are non-GAAP financial measures, for the 3rd quarter of 2022. Those proforma non-GAAP financial measures are intended to report the financial impact of the merger with SeaSpine on Adjusted EBITDA and Adjusted Gross Margin as if the merger had occurred on January 1, 2022, in order to assist investors with comparing those proforma results to those same non-GAAP financial measures as reported for the 3rd quarter of 2023.

A reconciliation of proforma Adjusted EBITDA for each quarter of 2022 to the nearest GAAP financial measure for each of SeaSpine and Orthofix is presented on this slide.

For further information on the reasons for and nature of non-GAAP disclosures by Orthofix and descriptions of the adjustments used to calculate non-GAAP financial measures, please see the Company's Current Report on Form 8 K filed on November 8, 2023.

Historical 2022 Quarterly Proforma Adjusted Gross Margin

Proforma Historical Adjusted Gross Margin (\$ in millions)	Q1 22			Q2 22			Q3 22			Q4 22			FY 2022		
	OFIX	SPNE	NewCo	OFIX	SPNE	NewCo	OFIX	SPNE	NewCo	OFIX	SPNE	NewCo	OFIX	SPNE	NewCo
Total revenue, net	\$ 106.418	\$ 51.263	\$ 157.681	\$ 118.070	\$ 56.942	\$ 175.012	\$ 113.996	\$ 67.772	\$ 181.768	\$ 122.229	\$ 64.144	\$ 186.373	\$ 460.713	\$ 240.121	\$ 700.834
Gross profit ⁽¹⁾	\$ 78.100	\$ 28.966	\$ 107.066	\$ 86.470	\$ 35.768	\$ 122.238	\$ 83.423	\$ 38.585	\$ 122.008	\$ 89.176	\$ 38.515	\$ 127.691	\$ 337.169	\$ 141.834	\$ 479.003
Add back:															
Share-based compensation expense	0.211	0.078	0.289	0.204	0.082	0.286	0.195	0.103	0.299	0.217	0.102	0.318	0.827	0.365	1.192
SeaSpine merger-related costs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Strategic investments	0.025	-	0.025	0.566	-	0.566	0.304	-	0.304	0.439	-	0.439	1.334	-	1.334
Acquisition-related fair value adjustments	-	0.125	0.125	-	0.083	0.083	-	-	-	-	-	-	-	0.208	0.208
Amortization/depreciation of acquired long-lived assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Medical device regulation	0.006	-	0.006	0.008	-	0.008	-	-	-	0.001	-	0.001	0.015	-	0.015
Adjusted gross profit	\$ 78.342	\$ 29.169	\$ 107.511	\$ 87.248	\$ 35.933	\$ 123.181	\$ 83.922	\$ 38.688	\$ 122.611	\$ 89.833	\$ 38.617	\$ 128.450	\$ 339.345	\$ 142.407	\$ 481.752
Adjusted gross margin (Adjusted gross profit / Total revenue, net)	73.6%	56.9%	68.2%	73.9%	63.1%	70.4%	73.6%	57.1%	67.5%	73.5%	60.2%	68.9%	73.7%	59.3%	68.7%

(1) SeaSpine gross profit reflects reclassifications of certain expenses to conform to Orthofix presentation.

On the Company's Q3 2023 earnings call held on November 8, 2023, Orthofix management presented Proforma Adjusted EBITDA and Adjusted Proforma Gross Margin, both of which are non-GAAP financial measures, for the 3rd quarter of 2022. Those proforma non-GAAP financial measures are intended to report the financial impact of the merger with SeaSpine on Adjusted EBITDA and Adjusted Gross Margin as if the merger had occurred on January 1, 2022, in order to assist investors with comparing those proforma results to those same non-GAAP financial measures as reported for the 3rd quarter of 2023.

A reconciliation of proforma Adjusted EBITDA for each quarter of 2022 to the nearest GAAP financial measure for each of SeaSpine and Orthofix is presented on this slide.

For further information on the reasons for and nature of non-GAAP disclosures by Orthofix and descriptions of the adjustments used to calculate non-GAAP financial measures, please see the Company's Current Report on Form 8 K filed on November 8, 2023.